# Altimmune (ALT) — Earnings

ALT · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/alt/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q2 2026 |
| Period end | Jun 30, 2026 |
| EPS actual | −$0.12 |
| EPS estimate | −$0.14 |
| EPS surprise | +11.44% |
| Revenue surprise | +0.00% |
| Revenue | $0.00 |
| Revenue estimate | $0.00 |
| Reported | Aug 12, 2026 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/1326190/000132619026000052/alt-20260630x10q.htm) |
| Earnings call | [Transcript](http://o.thsi.cn/dc-d-stock-america.teleconference/38717cfa-b341-e8fc-a869-56d0b49023e1.html) |

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q2 2026 | Aug 12, 2026 | −$0.14 | −$0.12 | 11.44% | — | — |
| Q1 2026 | May 13, 2026 | −$0.24 | −$0.18 | 25.71% | $1,429.00 | — |
| Q4 2025 | Mar 5, 2026 | −$0.23 | −$0.27 | -15.38% | $556.00 | $26,000.00 |
| Q3 2025 | Nov 6, 2025 | −$0.27 | −$0.21 | 22.82% | $1,429.00 | $5,000.00 |
| Q2 2025 | Aug 12, 2025 | −$0.34 | −$0.27 | 19.69% | $1,429.00 | $5,000.00 |
| Q1 2025 | May 13, 2025 | −$0.35 | −$0.26 | 26.12% | — | $5,000.00 |
| Q4 2024 | Feb 27, 2025 | −$0.33 | −$0.33 | 0.75% | — | $5,000.00 |
| Q3 2024 | Nov 12, 2024 | −$0.36 | −$0.32 | 10.26% | $714.00 | $5,000.00 |
| Q2 2024 | Aug 8, 2024 | −$0.35 | −$0.35 | -0.40% | $714.00 | $5,000.00 |
| Q1 2024 | May 9, 2024 | −$0.37 | −$0.34 | 8.11% | — | $5,000.00 |
| Q4 2023 | Mar 27, 2024 | −$0.46 | −$0.54 | -18.68% | $2,143.00 | $37,000.00 |
| Q3 2023 | Nov 7, 2023 | −$0.45 | −$0.39 | 13.81% | $857.00 | $362,000.00 |
| Q2 2023 | Aug 10, 2023 | −$0.47 | −$0.32 | 31.18% | $3,000.00 | $6,000.00 |
| Q1 2023 | May 11, 2023 | −$0.48 | −$0.40 | 16.67% | — | $21,000.00 |
| Q4 2022 | Feb 28, 2023 | −$0.50 | −$0.43 | 14.24% | $28,857.00 | — |
| Q3 2022 | Nov 10, 2022 | −$0.51 | −$0.48 | 4.95% | $867,833.00 | $2,000.00 |
| Q2 2022 | Aug 11, 2022 | −$0.50 | −$0.42 | 16.00% | $871,500.00 | $8,000.00 |
| Q1 2022 | May 12, 2022 | −$0.59 | −$0.44 | 25.42% | $1.0M | $32,000.00 |
| Q4 2021 | Mar 15, 2022 | −$0.66 | −$0.57 | 13.64% | $90,333.00 | $3.3M |
| Q3 2021 | Nov 9, 2021 | −$0.45 | −$0.81 | -81.74% | $70,667.00 | $157,559.00 |

## Frequently Asked Questions

### When did Altimmune (ALT) last report earnings?

Altimmune last reported on Aug 12, 2026, covering fiscal Q2 2026.

### Did ALT beat earnings estimates?

Yes. Altimmune reported EPS of −$0.12 for Q2 2026 against a −$0.14 estimate — a 11.44% beat.

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).